Published in J Immunol on April 01, 1981
Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med (1982) 2.42
Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med (1982) 1.76
Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J Exp Med (1986) 1.62
Cloning, sequence, and expression of bovine interleukin 2. Proc Natl Acad Sci U S A (1986) 1.10
Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone. Proc Natl Acad Sci U S A (1982) 1.00
Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J Exp Med (1994) 0.94
Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors. Cancer Invest (2011) 0.89
Interleukin 2 augmentation of natural killer cell activity in homosexual men with acquired immune deficiency syndrome. Infect Immun (1984) 0.85
Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology (1998) 0.84
Amplification of altered self-reactive cytolytic T lymphocyte responses by cloned, allospecific human Th cells. J Clin Invest (1988) 0.82
Lysis of primary hepatic tumours by lymphokine activated killer cells. Gut (1987) 0.80
In vitro and in vivo actions of acetylcholine receptor educated suppressor T cell lines in murine experimental autoimmune myasthenia gravis. Clin Exp Immunol (1984) 0.78
Lethal effect of the intravenous injection of H-2 alloantigen activated T cells. Clin Exp Immunol (1982) 0.77
Lymphokine-activated killer cytotoxicity against leukaemic blast cells. Clin Exp Immunol (1990) 0.75
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med (1995) 10.04
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (1992) 7.04
The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods (1990) 6.52
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09
The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J Immunol (2000) 6.00
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 5.42
Bone-marrow transplantation (second of two parts). N Engl J Med (1975) 4.11
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med (1996) 3.88
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med (1979) 3.59
Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol (1999) 3.33
Bone-marrow transplantation (first of two parts). N Engl J Med (1975) 3.33
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med (2000) 3.32
Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med (1985) 2.65
In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med (1999) 2.58
Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol (1994) 2.50
Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med (1981) 2.50
One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood (1977) 2.36
Peroxidase-H2O2-halide system: Cytotoxic effect on mammalian tumor cells. Blood (1975) 2.25
Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J Immunol (1993) 2.25
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol (1980) 2.20
Retracted HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest (2000) 2.17
Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol (1991) 2.16
Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature (1996) 2.14
Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells. J Immunol (1975) 2.06
CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A (1999) 1.93
Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol (1995) 1.91
Severe babesiosis in Long Island: review of 34 cases and their complications. Clin Infect Dis (2001) 1.89
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol (1997) 1.84
Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature (1994) 1.83
Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood (1985) 1.81
Allogeneic marrow grafting for treatment of aplastic anemia. Blood (1974) 1.76
Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med (1982) 1.76
Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol (2003) 1.70
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68
Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res (1999) 1.68
Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood (1996) 1.66
Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J Exp Med (1986) 1.62
Hickman catheter infections in patients with malignancies. Medicine (Baltimore) (1984) 1.61
Induction and regression of primary moloney sarcoma virus-induced tumors in mice. Cancer Res (1967) 1.60
Safety of retroviral gene marking with a truncated NGF receptor. Nat Med (2003) 1.60
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A (1993) 1.58
Antigenicity of a virus-induced murine sarcoma (Moloney). Cancer Res (1967) 1.58
Immunologic, virologic, and pathologic studies of regression of autochthonous Moloney sarcoma virus-induced tumors in mice. Cancer Res (1968) 1.57
Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope (2000) 1.51
Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol (1993) 1.51
Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol (1996) 1.50
Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Proc Natl Acad Sci U S A (1993) 1.50
The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol (2000) 1.49
Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood (1998) 1.49
Interstitial pneumonia and cytomegalovirus infection as complications of human marrow transplantation. Transplantation (1973) 1.48
Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol (2000) 1.47
Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med (1979) 1.44
Very low dose alpha-2b interferon for the treatment of hairy cell leukemia. Blood (1989) 1.41
Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med (1986) 1.41
Aplastic anaemia treated by marrow transplantation. Lancet (1972) 1.39
Cross-resistance to the transplantation of syngeneic Friend, Moloney, and Rauscher virus-induced tumors. Cancer Res (1968) 1.39
Prospects for adoptive T cell therapy. Curr Opin Immunol (1997) 1.38
Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J Virol (2001) 1.34
Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol (1996) 1.34
Oncogenic proteins as tumor antigens. Curr Opin Immunol (1996) 1.27
Efficacy of cryopreserved spleen cells in murine tumor immunotherapy. Transplantation (1972) 1.27
WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia (2003) 1.25
FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens. J Exp Med (1989) 1.25
Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med (1984) 1.24
Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol (1983) 1.23
Comparative studies on the induction of transplantation resistance in BALB-c and C57BL-6 mice in three murine leukemia systems. Cancer Res (1967) 1.22
Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Ann Intern Med (1984) 1.22
Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins. N Engl J Med (1974) 1.22
Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol (1986) 1.22
Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol (2001) 1.21
In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res (1994) 1.20
Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood (2000) 1.18
Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice. Cancer Res (1969) 1.17
Leukaemic transformation of engrafted human marrow cells in vivo. Lancet (1972) 1.17
Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen. J Immunol (2001) 1.15
Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells. J Immunol (1984) 1.15
HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res (1997) 1.13
The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science (1990) 1.13
Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle. Blood (1976) 1.11
The IL-2 receptor promotes proliferation, bcl-2 and bcl-x induction, but not cell viability through the adapter molecule Shc. J Immunol (1998) 1.11
Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol (1998) 1.10
Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol (1996) 1.10